Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director · Chief Executive Officer | March 13, 2026 | March 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kyverna Therapeutics, Inc.
Report date March 13, 2026 · Filed March 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,000 |
Reported balance
After 2026-03-13 transaction · row 1
1 source rowRow 1 · 2026-03-13 · Grant · Acquired 58,000 · Balance 58,000 F1: Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.95 · Expires 2036-03-13 | Direct | 350,000 |
Reported balance
After 2026-03-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-13 · Grant · Acquired 350,000 · Balance 350,000 F2: 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2026 Filed Mar 17, 2026 16:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 350,000 | $0.00 Strike: $8.95 | $0.00 |
DisclosureSEC source: 0001193125-26-110920 · ownership.xml · derivative · entry 2 Biddle Warner Weston · CIK 0002034523 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2036-03-13 F2 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 16:30 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantCommon Stock | 58,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-110920 · ownership.xml · nonDerivative · entry 1 Biddle Warner Weston · CIK 0002034523 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,000 F1 · shares: Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:18 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 2,579,259 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000950170-24-107968 · ownership.xml · derivative · entry 1 Biddle Warner Weston · CIK 0002034523 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,579,259 Underlying: Common Stock · 2,579,259 shares Expires 2034-09-16 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on September 16, 2025, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
| April 11, 2024 Filed Apr 15, 2025 17:42 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | GrantStock Option (right to buy) · Derivative | 332,500 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0000950170-25-054345 · ownership.xml · derivative · entry 1 Biddle Warner Weston · CIK 0002034523 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,500 Underlying: Common Stock · 332,500 shares Expires 2035-04-11 F1 · derivative.exercise_date: 1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.